Ezra Bendit, MD
Internal Medicine · Plainview, NYNPI 1528145034
Payments from drug & device makers
Across 136 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$607
- Amgen$350
- Pfizer$306
- Merck$265
- AstraZeneca$228
- Boston Scientific$154
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,89099%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $607 |
| Amgen | 16 | $350 |
| Pfizer | 17 | $306 |
| Merck | 12 | $265 |
| AstraZeneca | 13 | $228 |
| Boston Scientific | 2 | $154 |
| Novartis | 7 | $146 |
| Novo Nordisk | 5 | $123 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Eisai Inc. | 3 | $61 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $60 |
| Almatica Pharma LLC | 2 | $54 |
| Bayer | 2 | $53 |
| GSK | 3 | $52 |
| Philips North America LLC | 1 | $41 |
| Baxter Healthcare | 1 | $37 |
| Lilly USA, LLC | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Vistapharm, Inc. | 2 | $26 |
| Exact Sciences | 1 | $24 |
| Insightec,inc | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Renalytix AI, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Clarus Therapeutics Inc. | 1 | $20 |
| Abbott | 1 | $17 |
| Althera Pharmaceuticals LLC | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WALLSTENT$123
How this compares
$2,920 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 64 | $66,139 |
| EliquisApixaban | 64 | $53,394 |
| TrulicityDulaglutide | 31 | $44,652 |
| JardianceEmpagliflozin | 18 | $30,360 |
| MounjaroTirzepatide | 25 | $26,554 |
| XareltoRivaroxaban | 25 | $26,219 |
| FarxigaDapagliflozin Propanediol | 19 | $23,479 |
| JanuviaSitagliptin Phosphate | 13 | $18,230 |
| Repatha SureclickEvolocumab | 16 | $12,716 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,146 |
| SynthroidLevothyroxine Sodium | 109 | $7,209 |
| MyrbetriqMirabegron | 18 | $7,169 |
| Atorvastatin Calcium | 503 | $5,391 |
| Metoprolol Succinate | 294 | $4,830 |
| Rosuvastatin Calcium | 311 | $4,221 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $31 | $71,20556 claims |
| Novo NordiskOzempic | $123 | $66,13964 claims |
| PfizerEliquis | $306 | $53,39464 claims |
| Boehringer IngelheimJardiance | $22 | $30,36018 claims |
| AstraZenecaFarxiga | $228 | $23,47919 claims |
| MerckJanuvia | $265 | $18,23013 claims |
| GSKBreo Ellipta | $52 | $11,14621 claims |
| AbbVieSynthroid | $607 | $7,209109 claims |
| Almatica Pharma LLCSertraline Hcl | $54 | $1,451137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Plainview
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.